Suppression of farnesyltransferase activity in acute myeloid leukemia and myelodysplastic syndrome: Current understanding and recommended use of tipifarnib

Expert Opinion on Investigational Drugs

Volumn 19, Issue 5, 2010, Pages 689-698

  Epling Burnette, Pearlie K ^a   Loughran Jr , Thomas P ^b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b PENN STATE CANCER INSTITUTE   (United States)

Author keywords

Acute myeloid leukemia; Farnesyltransferase; Lipid; Myelodysplastic syndrome; Ras; Treatment

Indexed keywords

AMPHOTERICIN B; BIOLOGICAL MARKER; CYTARABINE; DAUNORUBICIN; DIURETIC AGENT; ETOPOSIDE; FARNESYL TRANS TRANSFERASE; PLACEBO; TIPIFARNIB;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ALOPECIA; AMYLASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; ATAXIA; BACKACHE; BACTERIAL INFECTION; BONE MARROW SUPPRESSION; BRAIN HEMORRHAGE; CATARACT; CLINICAL TRIAL; CONFUSION; CONSTIPATION; CONTINUOUS INFUSION; COUGHING; CREATININE BLOOD LEVEL; DEHYDRATION; DEPRESSION; DESQUAMATION; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSARTHRIA; DYSPEPSIA; DYSPHONIA; DYSPNEA; DYSURIA; EDEMA; ENZYME ACTIVITY; ENZYME REPRESSION; ERYTHEMA; EXTRAPYRAMIDAL SYNDROME; FATIGUE; FEBRILE NEUTROPENIA; FEVER; FLATULENCE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GRANULOCYTOPENIA; HEADACHE; HEART PALPITATION; HICCUP; HOT FLUSH; HUMAN; HYPERBILIRUBINEMIA; HYPERCALCEMIA; HYPERGLYCEMIA; HYPESTHESIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTENSION; ILEUS; INCIDENCE; INFECTION; INTESTINE OBSTRUCTION; INVOLUNTARY MOVEMENT; KIDNEY FAILURE; LACTATE DEHYDROGENASE BLOOD LEVEL; LEG PAIN; LETHARGY; LEUKOPENIA; LUNG HEMORRHAGE; LUNG INFILTRATE; MALAISE; MOOD DISORDER; MOTOR NEUROPATHY; MUSCLE WEAKNESS; MYALGIA; MYCOSIS; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUROTOXICITY; NONHUMAN; PAIN; PANCYTOPENIA; PARESTHESIA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHARYNGITIS; PHOTOSENSITIVITY; PNEUMONIA; POLYDIPSIA; PREDICTOR VARIABLE; PREVALENCE; RASH; RECOMMENDED DRUG DOSE; REVIEW; RIGOR; SEIZURE; SENSORY NEUROPATHY; SEPSIS; SIDE EFFECT; STOMATITIS; TACHYCARDIA; TASTE DISORDER; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT RESPONSE; TREMOR; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; URINARY TRACT INFECTION; VISUAL DISORDER; VOMITING; WEIGHT; XEROSTOMIA;

AGE FACTORS; ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; FARNESYLTRANSTRANSFERASE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; QUINOLONES;

EID: 77951466045     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543781003801076     Document Type: Review

References (58)

1. Xie Y, Davies SM, Xiang Y, et al. Trends in leukemia incidence and survival in the United States (1973-1998). Cancer 2003;97(9):2229-2235 (Pubitemid 36444065)
2. Greenberg PL, Young NS, Gatterman N, et al. Myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program 2002;136-161
3. Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 2007;109(8):1536-1542 (Pubitemid 46595689)
4. Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008;112(1):45-52
5. Mattison RJ, Ostler KR, Locke FL, Godley LA. Implications of FLT3 mutations in the therapy of acute myeloid leukemia. Rev Recent Clin Trials 2007;2(2):135-141 (Pubitemid 46773881)
6. Pinheiro RF, de Sa Moreira E, Silva MR, et al. FLT3 internal tandem duplication during myelodysplastic syndrome follow-up: a marker of transformation to acute myeloid leukemia. Cancer Genet Cytogenet 2008;183(2):89-93
7. Padua RA, Carter G, Hughes D, et al. RAS mutations in myelodysplasia detected by amplification, oligonucleotide hybridization, and transformation. Leukemia 1988;2(8):503-510
8. Ehmann F, Horn S, et al. Detection of N-RAS and K-RAS in their active GTP-bound form in acute myeloid leukemia without activating RAS mutations. Leuk Lymphoma 2006;47(7): 1387-1391 (Pubitemid 44269650)
9. Recher C, Dos Santos C, et al. mTOR, a new therapeutic target in acute myeloid leukemia. Cell Cycle 2005;4(11):1540-1549 (Pubitemid 41609135)
10. Faderl S, Pal A, Bornmann W, et al. Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cells. Cancer Res 2009;69(9):3910-3917
11. Dickson DJ, Shami PJ. Angiogenesis in acute and chronic leukemias. Leuk Lymphoma 2001;42(5):847-853
12. Lancet JE, Karp JE. Farnesyl transferase inhibitors in myeloid malignancies. Blood Rev 2003;17(3):123-129 (Pubitemid 36876672)
13. Saglio G, Serra A, Novarino A, et al. N-ras mutations in myeloid leukemias. Tumori 1989;75(4):337-340 (Pubitemid 19260347)
14. Auewarakul CU, Lauhakirti D, Tocharoentanaphol C. Frequency of RAS gene mutation and its cooperative genetic events in Southeast Asian adult acute myeloid leukemia. Eur J Haematol 2006;77(1):51-56 (Pubitemid 43876205)
15. Bacher U, Haferlach T, Schoch C, et al. Implications of NRAS mutations in AML: a study of 2502 patients. Blood 2006;107(10):3847-3853 (Pubitemid 43726786)
16. Niimi H, Harada H, Harada Y, et al. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations. Leukemia 2006;20(4):635-644
17. Paquette RL, Landaw EM, Pierre RV, et al. N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome. Blood 1993;82(2):590-599
18. Neubauer A, Greenberg P, Negrin R, et al. Mutations in the ras proto-oncogenes in patients with myelodysplastic syndromes. Leukemia 1994;8(4):638-641 (Pubitemid 24133031)
19. Padua RA, West RR. Oncogene mutation and prognosis in the myelodysplastic syndromes. Br J Haematol 2000;111(3):873-874
20. Reuter CW, Morgan MA, Bergmann L. Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood 2000;96(5):1655-1669 (Pubitemid 30661043)
21. Li N, Batzer A, Daly R, et al. Guanine-nucleotide-releasing factor hSos1 binds to Grb2 and links receptor tyrosine kinases to Ras signalling. Nature 1993;363(6424):85-88 (Pubitemid 23144968)
22. de Rooij J, Bos JL. Minimal Ras-binding domain of Raf1 can be used as an activation-specific probe for Ras. Oncogene 1997;14(5):623-625 (Pubitemid 27090966)
23. Basso AD, Kirschmeier P, Bishop WR. Lipid posttranslational modifications. Farnesyl transferase inhibitors. J Lipid Res 2006;47(1):15-31
24. Agrawal AG, Somani RR. Farnesyltransferase inhibitor as anticancer agent. Mini Rev Med Chem 2009;9(6):638-652
25. Lerner EC, Qian Y, Blaskovich MA, et al. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras-Raf complexes. J Biol Chem 1995;270(45):26802-26806 (Pubitemid 3007240)
26. Lerner EC, Zhang TT, Knowles DB, et al. Inhibition of the prenylation of K-Ras, but not H-or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines. Oncogene 1997;15(11):1283-1288
27. Bolick SC, Landowski TH, Boulware D, et al. The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells. Leukemia 2003;17(2):451-457 (Pubitemid 36266924)
28. Santucci R, Mackley PA, Sebti S, Alsina M. Farnesyltransferase inhibitors and their role in the treatment of multiple myeloma. Cancer Control 2003;10(5):384-387 (Pubitemid 37296065)
29. Tamanoi F. Inhibitors of Ras farnesyltransferases. Trends Biochem Sci 1993;18(9):349-353 (Pubitemid 23258293)
30. Sebti SM, Hamilton AD. Rational design of Ras prenyltransferase inhibitors as potential anticancer drugs. Biochem Soc Trans 1996;24(3):692-699
31. Norman P. Tipifarnib (Janssen Pharmaceutica). Curr Opin Investig Drugs 2002;3(2):313-319
32. Mesa RA, Tefferi A, Gray LA, et al. In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia. Leukemia 2003;17(5):849-855 (Pubitemid 36626310)
33. Le Gouill S, Pellat-Deceunynck C, Harousseau JL, et al. Farnesyl transferase inhibitor R115777 induces apoptosis of human myeloma cells. Leukemia 2002;16(9): 1664-1667
34. Cortes J, Albitar M, Thomas D, et al. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 2003;101(5):1692-1697 (Pubitemid 36237561)
35. Ochiai N, Uchida R, Fuchida S, et al. Effect of farnesyl transferase inhibitor R115777 on the growth of fresh and cloned myeloma cells in vitro. Blood 2003;102(9):3349-3353 (Pubitemid 37314777)
36. Alsina M, Fonseca R, Wilson EF, et al. Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood 2004;103(9):3271-3277 (Pubitemid 38525650)
37. Mor A, Dustin ML, Phillips MR, et al. Small GTPases and LFA-1 reciprocally modulate adhesion and signaling. Immunol Rev 2007;218:114-125
38. End DW, Smets G, Todd AV, et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 2001;61(1):131-137
39. Karp JE, Lancet JE, Kaufmann SH, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood 2001;97(11):3361-3369
40. Patnaik A, Eckhardt SG, Izbicka Z, et al. A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies. Clin Cancer Res 2003;9(13):4761-4771
41. Crul M, de Klerk GJ, Smart M, et al. Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 2002;20(11):2726-2735
42. Karp JE, Flatten K, Feldman EJ, et al. Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide. Blood 2009;113(20):4841-4852
43. Brandwein JM, Leber BF, Howson-Jan K, et al. A phase 1 study of tipifarnib combined with conventional induction and consolidation therapy for previously untreated patients with Acute Myeloid Leukemia aged 60 years and over. Leukemia 2009;23(4):631-634
44. Harousseau JL, Lancet JE, Reiffers J, et al. A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia. Blood 2007;109(12):5151-5156
45. Harousseau JL, Martinelli G, Jadrzejczak WW, et al. A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. Blood 2009;114(6):1166-1173
46. Erba HP, Kopecky KJ, Kirschbaum MH, et al. Phase II studies of different schedules and doses of the farnesyl transferase inhibitor tipifarnib (R115777, Zarnestra, NSC-702818) for patients of age 70 or older with previously untreated acute myeloid leukemia (AML): a North American Intergroup Study (SO432). ASH Annual Meeting Abstracts 2007;110:440
47. Karp JE, Smith BD, Gojo I, et al. Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features. Clin Cancer Res 2008;14(10):3077-3082
48. Raponi M, Lancet JE, Fan H, et al. A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. Blood 2008;111(5):2589-2596
49. Gueven N, Becherel OJ, Kijas AW, et al. Aprataxin, a novel protein that protects against genotoxic stress. Hum Mol Genet 2004;13(10):1081-1093
50. Schellens J, Palmer P, Selfert W, et al. A phase 1 study to determine the safety and MTD of chronic oral administration of farnesyltransferase inhibitor R115777 in patients with advanced cancer. JRF Clinical Research Reports 2001. R115777-BEL, EDMS-BEBE-2341152
51. Punt C, Palmer P, Seifert W, et al. A Phase-I study to determine the safety and maximum tolerated dose of 28 days oral administration of farnesyltransferase inhibitor R115777 in subjects with advanced cancer. JRF Clinical Research Rep Synopsis R115777-BEL-7 (terminated study), October 2000. EDMS-BEBE-1834493
52. Horak I, Bowden C, Palmer P, et al. Phase I trial to determine the safety and pharmacokinetics of R115777, a farnesyltransferase inhibitor. JRF Clinical Research Report R115777-USA-1, October 2000. EDMS-USTI-2338340
53. Richards H, Thibault A, Jia X, et al. A phase I trial to determine the safety and pharmacokinetics of 21-day dosing of a farnesyltransferase inhibitor, R115777 (ZARNESTRA™). JRF Clinical Research Report R115777-USA-3, July 2001. EDMS-USTI-2474164
54. Van de Velde H, Thibault A, Hoffman K, et al. A pilot phase 2 study of farnesyltransferase inhibitor R115777 in subjects with superficial bladder cancer. JRF Clinical Research Report R115777-USA-7, 2003. EDMS-PSDB-1500663
55. Richards H, De Porre P, Thibault A, et al. A phase 2 trial to determine the antitumor activity of farnesyltransferase inhibitor R115777 in subjects with relapsed small cell lung cancer. JRF Clinical Research Report R115777-USA-8, 2002. EDMS-PSDB-1508187
56. Howes A, Michiels B, Zannikos P, et al. An open study of the efficacy, safety and pharmacodynamics of the farnesyl protein inhibitor, R115777, in advanced breast cancer. JRF Clinical Research Report R1157777-GBR-1, September 2003, EDMS-PSDB-1675498
57. Palmer P, Kerstens R, Zannikos P, et al. A phase 2 trial of R115777, an oral farnesyltransferase inhibitor (FTI), in subjects with advanced urothelial tract transitional cell carcinoma. J&JPRD Clinical Study Report R115777-INT-10, 2003. EDMS-PSDB-2125081
58. Palmer P, Thibault A, Zannikos P, et al. A randomized, double-blind, placebo-controlled Phase 3 study of chronic oral adminstration of farnesyltransferase inhibitor R11577 plus supportive care versus supportive care alone in subjects with advanced colorectal cancer, after chemotherapy failure. J&JPRD Clinical Study report R115777-INT-9, 2003. EDMS-PSDB-1814193